KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Cash & Equivalents (2016 - 2026)

CareDx's Cash & Equivalents history spans 14 years, with the latest figure at $77.9 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 12.19% to $77.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $77.9 million, a 12.19% decrease, with the full-year FY2025 number at $65.4 million, down 42.95% from a year prior.
  • Cash & Equivalents hit $77.9 million in Q1 2026 for CareDx, up from $65.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CDNA hit a ceiling of $171.9 million in Q1 2022 and a floor of $65.4 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $95.5 million across 5 years, with a median of $88.7 million in 2025.
  • Biggest five-year swings in Cash & Equivalents: tumbled 76.5% in 2022 and later skyrocketed 39.53% in 2024.
  • Tracing CDNA's Cash & Equivalents over 5 years: stood at $89.9 million in 2022, then decreased by 8.59% to $82.2 million in 2023, then skyrocketed by 39.53% to $114.7 million in 2024, then tumbled by 42.95% to $65.4 million in 2025, then increased by 19.1% to $77.9 million in 2026.
  • Business Quant data shows Cash & Equivalents for CDNA at $77.9 million in Q1 2026, $65.4 million in Q4 2025, and $91.4 million in Q3 2025.